SCHEMBL17437838

SCHEMBL17437838

O=C(O)c1cnn2cc(N3CCC(F)C3)ccc12

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
NOTUM Q6P988 4/20 0.37
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
USP30 Q70CQ3 2/20 0.35
ROCK2 O75116 2/20 0.35
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
MAT2A P31153 1/20 0.34
MAT1A Q00266 1/20 0.34
POLB P06746 1/20 0.34
USP2 O75604 1/20 0.33
MYC P01106 2/20 0.33
WDR5 P61964 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17437836 1.00 KEAP1 (0.39) KEAP1NFE2L2NOTUMMAPTSMN1; SMN2
SCHEMBL17437907 1.00 KEAP1 (0.39) KEAP1NFE2L2NOTUMMAPTSMN1; SMN2
SCHEMBL17437916 0.91 KEAP1 (0.35) KEAP1NFE2L2MAPTSMN1; SMN2ALDH1A1
SCHEMBL17454484 0.90 USP30 (0.37) NOTUMMAPTSMN1; SMN2ALDH1A1USP30
SCHEMBL17454366 0.90 USP30 (0.37) NOTUMMAPTSMN1; SMN2ALDH1A1USP30
SCHEMBL19902552 0.86 ROCK2 (0.36) NOTUMSMN1; SMN2ALDH1A1USP30ROCK2
SCHEMBL17452620 0.86 ACACB (0.36) NOTUMALDH1A1USP30ROCK2DRD4
SCHEMBL19902684 0.86 ROCK2 (0.36) NOTUMSMN1; SMN2ALDH1A1USP30ROCK2
SCHEMBL17452622 0.86 ACACB (0.36) NOTUMALDH1A1USP30ROCK2DRD4
SCHEMBL17437897 0.81 IP6K1 (0.47) MAPTSMN1; SMN2ALDH1A1ROCK2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169682-B1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-12-26 EP disclosed
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed
EP-3169682-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2017-05-24 EP disclosed
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 US disclosed
WO-2016010950-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2016-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 KEAP1 247/4885NFE2L2 1220/4885NOTUM 2786/4885
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 KEAP1 247/4885NFE2L2 1220/4885NOTUM 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.